GSK-2646264

N/A

Report date: 2023/06/12 20:00:51
NME

Base Information

Drug NameGSK-2646264
Drug Alias NameGSK-2646264
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitors
TargetsSpleen tyrosine kinase
Therapy Area/IndicationsUrticariaLupus Erythematosus, Cutaneous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsUrticariaLupus Erythematosus, Cutaneous

Other Information

ATC CodeN/A
Related LinksN/A